Mark Davis, a microbiology and immunology professor at Stanford, emphasized that the current flu vaccine has shown effectiveness rates between 20% and 80%, mainly due to immunity being largely directed towards a single strain. He indicated this limitation poses a significant challenge as various flu strains circulate annually, thus necessitating innovative approaches to enhance vaccine efficacy across many more variants.
Bali Pulendran, a microbiology professor at Stanford, pointed out that human genetics often lead to a predisposed immune response towards one particular strain, leaving individuals vulnerable to others. His insights on the new vaccine design suggest it may help mitigate immunological biases, allowing for broader protection against the changing flu virus strains that people encounter each flu season.
Collection
[
|
...
]